Transgenic Mice: Transforming Targeted Monoclonal Antibody (mAb) Therapeutics

Download Full Whitepaper

Monoclonal antibodies (mAbs) currently represent the largest class of biopharmaceutical products. Market growth is projected to climb at least eight percent each year for the next several years, and the therapeutic antibody market is expected to reach $125 billion by 2020. With the right platform, antibodies are easy to isolate — the immune system generates a library of billions of different antibodies, each antibody with a unique specificity. To isolate attractive leads, scientists expose a host to the antigen of interest and then screen for binding and/or function. Genetically-engineered mice now act as robust engines for the generation of diverse repertoires of affinity-matured, fully-human variable regions with intrinsic drug-like properties necessary for successful development including high potency, specificity, manufacturability, solubility and low risk of immunogenicity. Few existing or contemplated human transgenic mouse platforms express a full human antibody repertoire. The Trianni Mouse is the only one to do so in a single organism. This approach guarantees efficient expression of the full human antibody repertoire and at the same time maintains the natural immune response of the wild-type mouse, allowing researchers to exploit advantages in terms of efficiency in drug discovery and development. Continue Reading…